Florbetaben (BAY94-9172) PET (Positron Emission Tomography) imaging in MCI (mild cognitive impairment) patients
The aim of the study is to investigate whether Florbetaben-BAY94-9172 positron emission tomography (PET) has any ability to distinguish patients with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from those with MCI not progressing to AD.
- Presence of MCI defined as abnormal cognition on objective testing in the absence of dementia or significant functional loss. - Absence of systemic or other neurological disease that may contribute to cognitive impairment or prevent follow-up over two years. - Able to give written informed consent. - Age >/= 60 years of age.
- Mini mental state examination (MMSE) score < 24 at baseline - Clinical dementia rating (CDR) score > 0.5 at baseline - Patients who receive regular medication of drugs which may adversely impact cognition (e.g. tricyclic antidepressants, antipsychotics and/or large doses of hypnotics or anxiolytics) - Existing or history of cancer - History of severe head trauma, brain surgery or intracranial hematoma with permanent brain lesion - Lifetime history of major affective disorder, schizophrenia, or schizo-affective disorder - Contraindications to MRI (Magnetic resonance imaging) - Relevant history, physical or imaging findings of neurological disease other than MCI and mild depression - History of severe anaphylactic reaction or high risk of allergic reaction to drugs - Patient has received another investigational drug in the preceding 14 days
Department of Nuclear Medicine and Centre for PET
Heidelberg, Australia, 3084
E-mail: [email protected]
Phone: Not Available
ß-amyloid imaging with BAY94-9172 positron emission tomography for early detection of Alzheimer's disease in patients with mild cognitive impairment
Single Group Assignment